4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

4 - Sierra Oncology, Inc. (0001290149) (Issuer)

HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $51.00 from $35.00 previously

Cantor Fitzgerald reiterated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $39.00 from $33.00 previously

HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $35.00 from $29.00 previously

Cantor Fitzgerald initiated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $33.00

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. "Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team designed a targeted study to address the highest unmet need and delivered incredible results in the midst of a pandemic. We are thrilled to submit this ND

– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also present with thrombocytopenia – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. "By entering into a merger agreement with GSK, we are one step closer to realizing our mission of delivering transformative therapies for patients with rare cancers, while also delivering compelling and certain value for our stockholders. We are working to continue to progress our timeline and our NDA submission remains on track for later this quarter," said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer at Sierra Oncology. Key

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze

Sierra Oncology's differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK's existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022 Sales contribution expected to start in 2023 with significant growth potential thereafter Supports development of strong portfolio of new specialty medicines and vaccines GlaxoSmithKline plc (NYSE:GSK) and Sierra Oncology, Inc (NASDAQ:SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a Cali

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The employees received options to purchase a total 55,500 shares of Sierra's common stock. The options have an exercise price of $33.76 per share

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview of the company on Tuesday, March 15, 2022, beginning at 3:20 pm ET. A replay of the presentation will be available following the conference on the Investors section of Sierra's corporate website in the Events & Webcast tab. The replay will be available for approximately 30 days following the presentation. About Sierra Oncology

– Planned Q2 2022 NDA submission following positive topline data from MOMENTUM clinical trial of momelotinib in symptomatic and anemic myelofibrosis patients – – Financial position significantly strengthened – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021. "Last year was a great year for Sierra. We accelerated timelines in the midst of a global pandemic to over enroll the pivotal MOMENTUM clinical trial, achieving statistical significance in the primary and all pre-specified secondary e

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The employees received options to purchase a total 43,500 shares of Sierra's common stock. The options have an exercise price of $31

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decade. Mr. Nicols will remain on Codexis' Board through the ann

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Addex Stops Parkinson's-Associated Dyskinesia Trial Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to slow recruitment of patients. The company plans to advance its preclinical portfolio toward the clinic and pursue strategic collaborations for selected programs. Shares were down 52.47% at $1.59 Friday morning.  Rhythm's Setmelanotide Scores FDA Approval For Expanded Use In Bardet-Biedl Syndrome The FDA approved Rhythm Pharmaceuticals Inc's (NASDAQ:RYTM) Imcivree (setmelanotide), a me

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online. An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for an oral presentation on June 7. An additional subset analysis from the trial evaluating safety and efficacy for patients with low platelet counts has been selected for poster presentation. "Receiving an oral p

  Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Sierra Oncology missed estimated earnings by 29.13%, reporting an EPS of $-1.33 versus an estimate of $-1.03. Revenue was down $0.00 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.1 which was followed by a 6.72% increase in the share price the next day.   To track all earnings releases for Sierra Oncology visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. This is a 8.9 percent increase over losses of $(1.46) per share from the same period last year.

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season. Lyra Therapeutics, Inc. (NASDAQ:LYRA) was among the biggest gainers of the week following the completion of a $100.5 million private placement. Sierra Oncology, Inc. (NASDAQ:SRRA) also advanced strongly after it announced a deal to be acquired by GlaxoSmithKline plc (NYSE:GSK) for $1.9 billion. Meanwhile, Kaleido Biosciences, Inc. (NASDAQ:KLDO) plunged after disclosing in a filing that it is shuttering operations. The microbiome therapeutic-focused biopharma was facing a cash crunch

Upgrades For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago quarter EPS of $2.66. The stock has a 52-week-high of $233.72 and a 52-week-low of $174.70. At the end of the last trading period, United Parcel Service closed at $188.87. According to WestPark Capital, the prior rating for Paysafe Ltd (NYSE:PSFE) was changed from Hold to Buy. The stock has a 52-week-high of $14.30 and a 52-week-low of $2.58. At the end of the last trading period, Paysafe closed at $3.25. Baird upgraded the previous rating for H.B. Fuller Co (NYSE:FUL) from Neutral to Outperf

Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 0 0 Last 30D 0 0 2 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 According to 5 analyst offering 12-month price targets in the last 3 months, Sierra Oncology has an average price target of $52.2 with a high of $55.00 and a low of $45.00. Below is a summary of how these 5 analysts rated Sierra Oncology over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts a

Sierra Oncology Inc's (NASDAQ:SRRA) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 11.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short